06 May 2026
As fentanyl drives overdose deaths, rapid testing is essential
Now in its third wave, the U.S. opioid epidemic remains a major public health crisis. Labcorp data reveals that between 2024 and 2025, approximately 4% of pre-employment screenings tested positive for fentanyl, and nearly 10% of patients in opioid use disorder (OUD) treatment tested positive for fentanyl. Even more alarming, nearly 70% of opioid-related overdose deaths involve synthetic opioids like fentanyl. Highly potent, fentanyl can be lethal in amounts as little as 2 milligrams, or the size of two grains of table salt. Fentanyl is also frequently mixed into illicit drugs or pressed into counterfeit pills, creating risk for unsuspecting users and complex challenges for healthcare providers. Naloxone remains a critical reversal medication, but fentanyl’s potency often requires multiple doses.
Rapid detection of fentanyl exposure is essential for determining appropriate treatment and guiding medication-assisted interventions. To support these needs, Labcorp has introduced a new FDA-cleared rapid fentanyl screening option through MEDTOX Diagnostics, a Labcorp company that specializes in point-of-care testing solutions.
Rapid results to support informed clinical decisions
Labcorp’s Fentanyl Urine Visual Test provides results in 10 minutes, allowing providers in both critical care and clinic settings to respond quickly when fentanyl exposure is suspected.
“Rapid test solutions that detect fentanyl metabolites in urine give providers timely answers that can inform treatment decisions,” says Heather Tabangcura, associate vice president and head of diagnostic devices at Labcorp. Early confirmation of fentanyl exposure enables the appropriate use of medications such as naloxone, supports access to overdose reversal care packs for future scenarios. It also helps guide counseling, crucial while the patient is still under care.
Why fast fentanyl detection matters in critical settings
Clinicians increasingly face cases of fentanyl-only exposure or fentanyl combined with other opioids. If a provider does not explicitly test for fentanyl, critical information may be missed. Traditional urine immunoassays can take more than an hour, and confirmatory mass spectrometry testing may take days, introducing delays that limit usefulness in time-sensitive encounters.
Rapid fentanyl testing supports real-time clinical decisions, including:
- Evaluating next steps for follow-up testing and treatment plans
- Providing patient education on overdose risks and naloxone use
- Supporting decisions on whether multiple naloxone doses may be required
Although naloxone is now available over the counter, the cost can be significant. Knowing a patient has been exposed to fentanyl can help justify having multiple doses on hand, which may be lifesaving.
Introducing the Labcorp Fentanyl Urine Visual Test
Developed by MEDTOX Diagnostics, the Labcorp Fentanyl Urine Visual Test detects norfentanyl, the primary fentanyl metabolite, with greater than 96% accuracy. The test offers a 48-hour detection window, providing a broader time frame than many competing fentanyl tests that detect only fentanyl and exclude norfentanyl. This extended detection period provides the widest possible opportunity to detect the largest number of patients with fentanyl exposure.
Key features of the Labcorp Fentanyl Urine Visual Test
- FDA-cleared, CLIA moderate complexity
- Results available in 10 minutes
- Greater than 96% accuracy detecting norfentanyl
- 48-hour detection window, even after fentanyl itself is no longer detected
- Convenient, accurate, and easy to use
Rapid, accurate tests like this help healthcare providers respond quickly to suspected fentanyl exposure, improve overdose management, and support more effective addiction treatment.
Supporting providers caring for patients with OUD
Federal funding for opioid response programs continues to grow, yet access to effective treatment remains limited. Understanding that comprehensive care for OUD requires more than urine drug testing, Labcorp offers a full suite of medication-assisted treatment (MAT) panels, along with testing for designer and synthetic drugs.
“Labcorp provides the expertise to help providers who are not specifically trained in toxicology know more about what urine drug test results mean,” says Dr. Karla Walker, discipline director of clinical toxicology at Labcorp. “We don’t just interpret test results; we also help providers understand the limitations of certain tests and fill information gaps.”
Providers can access Labcorp’s team of toxicologists seven days a week at 866-593-0157 for support interpreting complex results or understanding test limitations.
As fentanyl continues to drive overdoses, Labcorp remains committed to equipping clinicians with timely, actionable data to improve treatment outcomes for patients with OUD.